The emerging role of CDK4/6i in HER2-positive breast cancer

Prior to the advent of the monoclonal antibody trastuzumab, human epidermal growth-factor receptor 2 (HER2)-positive (HER2+) breast cancer (BC) was associated with an aggressive clinical course and poor survival outcomes. In the era of effective HER2-directed therapies, median survival rates for pat...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Ther Adv Med Oncol
Asıl Yazarlar: O’Sullivan, Ciara C., Suman, Vera J., Goetz, Matthew P.
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: SAGE Publications 2019
Konular:
Review
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC6887797/
https://ncbi.nlm.nih.gov/pubmed/31832106
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/1758835919887665
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller